BIT
CLLS

BlackRock Institutional Trust’s Cellectis CLLS Stock Holding History

BlackRock Institutional Trust’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,419
Closed -$419K – 3844
2016
Q3 		$419K Buy
+17,419
New +$455K ﹤0.01% 3520

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock Institutional Trust's CLLS Position: Q4 2016 in Review

BlackRock Institutional Trust sold out of Cellectis (CLLS) in Q4 2016, closing a stake of 17,419 shares — an estimated $419K sold.

BlackRock Institutional Trust first reported a position in CLLS in Q3 2016 and held it in 1 quarter. The position peaked at $419K in Q3 2016. 37 funds tracked by Wall St. Rank hold CLLS as of Q4 2016.

  • BlackRock Institutional Trust reported no remaining Cellectis position as of Q4 2016 after selling out during the quarter.
  • BlackRock Institutional Trust sold 17,419 Cellectis shares in Q4 2016, an estimated $419K.
  • BlackRock Institutional Trust first reported a position in Cellectis in Q3 2016 and held it in 1 quarter.
  • BlackRock Institutional Trust's Cellectis position peaked at $419K in Q3 2016.
  • 37 funds tracked by Wall St. Rank held Cellectis as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.